Hye Jin Wang
Taiwan
Research Article
Discovery of DiPeptidyl Peptidase-4 Gene Variants and the Associations with Efficacy of Vildagliptin in Patients with Type 2 Diabetes - A Pilot Study
Author(s): Obin Kwon, Eun Yeong Choe, Younjeong Choi, Hyun Min Kim, Hye Jin Wang, Hyangkyu Lee, Chul Hoon Kim and Eun Seok KangObin Kwon, Eun Yeong Choe, Younjeong Choi, Hyun Min Kim, Hye Jin Wang, Hyangkyu Lee, Chul Hoon Kim and Eun Seok Kang
Background: The dipeptidyl peptidase-4 (DPP4) inhibitors have become widely used antidiabetic medication. They control glycemia by interacting with serum DPP4 to interfere catalyzation of incretins. The aim of this pilot study was to discover the DPP4 polymorphisms that could affect the efficacy of vildagliptin, a DPP-4 inhibitor in diabetic patients.
Methods: Genetic variations in DPP4 were identified in 48 patients with type 2 diabetes who received vildagliptin treatment at least 12 weeks following metformin monotherapy. Luciferase assay was performed to estimate the effect of the regulatory single nucleotide polymorphism (SNP) on expression of DPP4.
Results: Eight tagging SNPs were genotyped in a sample of 24 patients. Additional sample of 24 patients was used to discover further regulatory SNPs and coding SNPs. In all 48 patients, responders (degree of HbA1c and/or.. View More»
